Cargando…
Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways
Disabled-2 (DAB2), a key adaptor protein in clathrin mediated endocytosis, is implicated in the regulation of key signalling pathways involved in homeostasis, cell positioning and epithelial to mesenchymal transition (EMT). It was initially identified as a tumour suppressor implicated in the initiat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821069/ https://www.ncbi.nlm.nih.gov/pubmed/36614139 http://dx.doi.org/10.3390/ijms24010696 |
_version_ | 1784865609963536384 |
---|---|
author | Price, Zoe K. Lokman, Noor A. Yoshihara, Masato Kajiyama, Hiroaki Oehler, Martin K. Ricciardelli, Carmela |
author_facet | Price, Zoe K. Lokman, Noor A. Yoshihara, Masato Kajiyama, Hiroaki Oehler, Martin K. Ricciardelli, Carmela |
author_sort | Price, Zoe K. |
collection | PubMed |
description | Disabled-2 (DAB2), a key adaptor protein in clathrin mediated endocytosis, is implicated in the regulation of key signalling pathways involved in homeostasis, cell positioning and epithelial to mesenchymal transition (EMT). It was initially identified as a tumour suppressor implicated in the initiation of ovarian cancer, but was subsequently linked to many other cancer types. DAB2 contains key functional domains which allow it to negatively regulate key signalling pathways including the mitogen activated protein kinase (MAPK), wingless/integrated (Wnt) and transforming growth factor beta (TGFβ) pathways. Loss of DAB2 is primarily associated with activation of these pathways and tumour progression, however this review also explores studies which demonstrate the complex nature of DAB2 function with pro-tumorigenic effects. A recent strong interest in microRNAs (miRNA) in cancer has identified DAB2 as a common target. This has reignited an interest in DAB2 research in cancer. Transcriptomics of tumour associated macrophages (TAMs) has also identified a pro-metastatic role of DAB2 in the tumour microenvironment. This review will cover the broad depth literature on the tumour suppressor role of DAB2, highlighting its complex relationships with different pathways. Furthermore, it will explore recent findings which suggest DAB2 has a more complex role in cancer than initially thought. |
format | Online Article Text |
id | pubmed-9821069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98210692023-01-07 Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways Price, Zoe K. Lokman, Noor A. Yoshihara, Masato Kajiyama, Hiroaki Oehler, Martin K. Ricciardelli, Carmela Int J Mol Sci Review Disabled-2 (DAB2), a key adaptor protein in clathrin mediated endocytosis, is implicated in the regulation of key signalling pathways involved in homeostasis, cell positioning and epithelial to mesenchymal transition (EMT). It was initially identified as a tumour suppressor implicated in the initiation of ovarian cancer, but was subsequently linked to many other cancer types. DAB2 contains key functional domains which allow it to negatively regulate key signalling pathways including the mitogen activated protein kinase (MAPK), wingless/integrated (Wnt) and transforming growth factor beta (TGFβ) pathways. Loss of DAB2 is primarily associated with activation of these pathways and tumour progression, however this review also explores studies which demonstrate the complex nature of DAB2 function with pro-tumorigenic effects. A recent strong interest in microRNAs (miRNA) in cancer has identified DAB2 as a common target. This has reignited an interest in DAB2 research in cancer. Transcriptomics of tumour associated macrophages (TAMs) has also identified a pro-metastatic role of DAB2 in the tumour microenvironment. This review will cover the broad depth literature on the tumour suppressor role of DAB2, highlighting its complex relationships with different pathways. Furthermore, it will explore recent findings which suggest DAB2 has a more complex role in cancer than initially thought. MDPI 2022-12-31 /pmc/articles/PMC9821069/ /pubmed/36614139 http://dx.doi.org/10.3390/ijms24010696 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Price, Zoe K. Lokman, Noor A. Yoshihara, Masato Kajiyama, Hiroaki Oehler, Martin K. Ricciardelli, Carmela Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways |
title | Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways |
title_full | Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways |
title_fullStr | Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways |
title_full_unstemmed | Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways |
title_short | Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways |
title_sort | disabled-2 (dab2): a key regulator of anti- and pro-tumorigenic pathways |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821069/ https://www.ncbi.nlm.nih.gov/pubmed/36614139 http://dx.doi.org/10.3390/ijms24010696 |
work_keys_str_mv | AT pricezoek disabled2dab2akeyregulatorofantiandprotumorigenicpathways AT lokmannoora disabled2dab2akeyregulatorofantiandprotumorigenicpathways AT yoshiharamasato disabled2dab2akeyregulatorofantiandprotumorigenicpathways AT kajiyamahiroaki disabled2dab2akeyregulatorofantiandprotumorigenicpathways AT oehlermartink disabled2dab2akeyregulatorofantiandprotumorigenicpathways AT ricciardellicarmela disabled2dab2akeyregulatorofantiandprotumorigenicpathways |